<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02600325</url>
  </required_header>
  <id_info>
    <org_study_id>NL2015-003210-24</org_study_id>
    <nct_id>NCT02600325</nct_id>
  </id_info>
  <brief_title>Dutch Acute HCV in HIV Study (DAHHS-2): Grazoprevir/Elbasvir for Acute HCV</brief_title>
  <acronym>DAHHS-2</acronym>
  <official_title>Grazoprevir (MK-5172)+ Elbasvir (MK-8742) for the Treatment of Acute Hepatitis C Genotype 1/4. The Dutch Acute HCV in HIV Study (DAHHS-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New and recently EMA/FDA approved direct acting antiviral (DAA) combination therapies cure
      95% or more of the patients chronically infected with HCV genotype 1 and 4. Grazoprevir
      (MK-5172) and elbasvir (MK-8742) combination therapy is such a, albeit not yet EMA/FDA
      approved combination DAA therapy.

      It is likely that the synergistic effect of the host's immune response and antiviral therapy
      when given during the first 6 months of HCV infection makes antiviral therapy during acute
      HCV infection more effective. In this study the investigators would like to document that
      treatment of acute HCV with grazoprevir (MK-5172), elbasvir (MK-8742) is effective and can
      ben shortened from 12 to 8 weeks for HCV genotype 1 and 4 infection without substantial loss
      in efficacy.

      Study design and intervention:

      Prospective open label interventional clinical trial in which 80 acute HCV genotype 1 or 4
      patients co-infected with HIV will receive 8 weeks of grazoprevir and elbasvir (a once-daily
      combination tablet).

      Study population:

      80 Adult HIV positive patients with an acute HCV genotype 1 or 4 infection from 10 HIV
      treatment centers in the Netherlands and Belgium will be included.

      Primary endpoint: Sustained viral response (SVR) 12 weeks after the end of therapy in ITT
      study population (=genotype 1 and 4).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale:

      Over the last 2 years, the treatment of chronic HCV underwent an enormous change in a
      positive way. New and recently EMA approved direct acting antiviral (DAA) combination
      therapies cure as 95% or more of the patients chronically infected with HCV genotype 1 and 4.
      Grazoprevir (MK-5172) and elbasvir (MK-8742) combination therapy is such a combination DAA
      therapy. Two recent phase II and 1 phase III clinical trial showed that chronic HCV genotype
      1 can be cured with 12 weeks of combination therapy with grazoprevir and elabsvir with a 97%
      cure in HIV-HCV co-infected patients in the phase III C-Edge co-infection study. However,
      none of these new HCV therapies have been well studied for the treatment of acute HCV and are
      therefore not registered for this indication. The only treatment approved for acute HCV is
      interferon. Interferon based therapy for the treatment of HCV has been shown to be much more
      effective when given during the acute phase of the HCV infection than at a time when the
      infection has become chronic. A likely explanation for this difference in success for acute
      versus chronic HCV therapy is a substantial immune response that is present during the acute
      phase of HCV infection, but becomes exhausted during chronic infection. This potent immune
      response is broadly targeted against various HCV epitopes and eradicates approximately 20% of
      HCV infections within the first 12 to 18 months of infection. However, spontaneous cure of
      HCV becomes very rare after the first 12 to 18 months of infection due to immune exhaustion.
      It is likely that the synergistic effect of the host's immune response and antiviral therapy
      when given during the first 6 months of HCV infection makes direct acting antiviral therapy
      during acute HCV infection more effective.

      Objectives:

      To document that treatment of acute HCV with grazoprevir (MK-5172), elbasvir (MK-8742) is
      effective. To show that, due to the host's immune response at the time of an acute HCV
      infection, the duration of therapy with grazoprevir (MK-5172) and elbasvir (MK-8742) for
      acute HCV genotype 1 and 4 infections can be shortened from 12 to 8 weeks without substantial
      loss in efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Actual">January 11, 2019</completion_date>
  <primary_completion_date type="Actual">April 1, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SVR12 (Reinfection Not Considered Failure)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are not considered failure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SVR12 (Reinfection Equals Failure)</measure>
    <time_frame>week 12</time_frame>
    <description>Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are considered failure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Acute Hepatitis C</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Grazoprevir/elbasvir single tablet regimen (100/50mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Grazoprevir/Elbasvir 100mg/50mg</intervention_name>
    <description>Grazoprevir/Elbasvir 100mg/50mg</description>
    <arm_group_label>Treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. HIV positive

          2. Acute HCV genotype 1 or 4 infection (≤26 weeks old at the baseline visit)

        Exclusion Criteria:

          1. Not on cART and a CD4 &lt;500 at the time of screening

          2. Patients on cART for &gt;6 months with a HIV viral load &gt;400 copies

          3. Disallowed co-medication that cannot be stopped or replaced

          4. History of liver cirrhosis of any etiology. Inclusion of patients with a chronic
             well-controlled HBV (HBV-DNA &lt;below the limit of detection) is allowed if fibroscan
             excludes &gt;F1 fibrosis

          5. Protease inhibitor based and NNRTI based cART regimens are not allowed. Therefore, the
             inability to switch to a HAART regimen consisting of 2 nucleoside/tide reverse
             transcriptase inhibitors and an allowed third agent which can be raltegravir
             (Isentress®) 400mg BID, dolutegravir (Tivicay) 50mg QD or rilpivirine 25mg QD.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B Rijnders, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus MC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Tropical Medicine Antwerp (ITG)</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center (EMC)</name>
      <address>
        <city>Rotterdam</city>
        <state>Zuid Holland</state>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onze Lieve Vrouwe Gasthuis (OLVG)</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Slotervaart Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center (MUMC)</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radbout University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utrecht Medical University Center (UMCU)</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <results_first_submitted>January 11, 2019</results_first_submitted>
  <results_first_submitted_qc>April 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 8, 2019</results_first_posted>
  <last_update_submitted>April 16, 2019</last_update_submitted>
  <last_update_submitted_qc>April 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Erasmus Medical Center</investigator_affiliation>
    <investigator_full_name>Bart Rijnders</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Acute Hepatitis C</keyword>
  <keyword>Human Immunodeficiency virus</keyword>
  <keyword>Grazoprevir</keyword>
  <keyword>Elbasvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>MK-5172</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 26, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT02600325/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Grazoprevir/Elbasvir 100mg/50mg</title>
          <description>Grazoprevir/elbasvir single tablet regimen (100/50mg)
Grazoprevir/Elbasvir 100mg/50mg: Grazoprevir/Elbasvir 100mg/50mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>G/E 8 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>SVR12 (Reinfection Not Considered Failure)</title>
        <description>Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are not considered failure</description>
        <time_frame>12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Grazoprevir/elbasvir single tablet regimen (100/50mg)
Grazoprevir/Elbasvir 100mg/50mg: Grazoprevir/Elbasvir 100mg/50mg</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 (Reinfection Not Considered Failure)</title>
          <description>Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are not considered failure</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SVR12 (Reinfection Equals Failure)</title>
        <description>Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are considered failure</description>
        <time_frame>week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment Group</title>
            <description>Grazoprevir/elbasvir single tablet regimen (100/50mg)
Grazoprevir/Elbasvir 100mg/50mg: Grazoprevir/Elbasvir 100mg/50mg</description>
          </group>
        </group_list>
        <measure>
          <title>SVR12 (Reinfection Equals Failure)</title>
          <description>Sustained viral response (SVR) 12 weeks after the end of therapy in all patients who started treatment in which reinfections are considered failure</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>20 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treatment Group</title>
          <description>Grazoprevir/elbasvir single tablet regimen (100/50mg)
Grazoprevir/Elbasvir 100mg/50mg: Grazoprevir/Elbasvir 100mg/50mg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>traumatic rectal bleeding</sub_title>
                <description>Unrelated SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elective low back surgery</sub_title>
                <description>Unrelated SAE</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (2.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspepsia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatique</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>mood changes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>concentration impairment</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. B. J. A. Rijnders</name_or_title>
      <organization>Erasmus MC</organization>
      <phone>0</phone>
      <email>b.rijnders@erasmusmc.nl</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

